Toll-like receptor 4 stimulation initiates an inflammatory response that decreases cardiomyocyte contractility

Antioxidants and Redox Signaling

Volumn 15, Issue 7, 2011, Pages 1895-1909

  Avlas, Orna ^a,b   Fallach, Reut ^a,b   Shainberg, Asher ^a   Porat, Eyal ^b   Hochhauser, Edith ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; MOUSE; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEPTIC SHOCK; WILD TYPE;

ADAPTIVE IMMUNITY; ANIMALS; APOPTOSIS; ENDOTHELIAL CELLS; GENE KNOCKOUT TECHNIQUES; HUMANS; IMMUNITY, INNATE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LIPOPOLYSACCHARIDES; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; SEPSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

MUS;

EID: 80052015440     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2010.3728     Document Type: Review

References (157)

1. Akira S, Hoshino K, and Kaisho T. The role of Toll-like receptors and MyD88 in innate immune responses. J Endotoxin Res 6: 383-387, 2000. (Pubitemid 32241948)
2. Akira S and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4: 499-511, 2004. (Pubitemid 38931765)
3. Akira S, Uematsu S, and Takeuchi O. Pathogen recognition and innate immunity. Cell 124: 783-801, 2006. (Pubitemid 43261452)
4. Alexopoulou L, Holt AC, Medzhitov R, and Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738, 2001. (Pubitemid 33009951)
5. Anderson KV. Toll signaling pathways in the innate immune response. Curr Opin Immunol 12: 13-19, 2000. (Pubitemid 30093445)
6. Anderson KV, Jurgens G, and Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 42: 779-789, 1985. (Pubitemid 16083719)
7. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, and Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310, 2001. (Pubitemid 32641789)
8. Ao L, Zou N, Cleveland JC, Jr., Fullerton DA, and Meng X. Myocardial TLR4 is a determinant of neutrophil infiltration after global myocardial ischemia: mediating KC and MCP-1 expression induced by extracellular HSC70. Am J Physiol Heart Circ Physiol 297: H21-H28, 2009.
9. Ashida K, Miyazaki K, Takayama E, Tsujimoto H, Ayaori M, Yakushiji T, Iwamoto N, Yonemura A, Isoda K, Mochizuki H, Hiraide H, Kusuhara M, and Ohsuzu F. Characterization of the expression of TLR2 (toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease. J Atheroscler Thromb 12: 53-60, 2005.
10. Baumgarten G, Knuefermann P, Nozaki N, Sivasubramanian N, Mann DL, and Vallejo JG. In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like receptor-4. J Infect Dis 183: 1617-1624, 2001. (Pubitemid 32466699)
11. Beutler B, Hoebe K, Du X, and Ulevitch RJ. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 74: 479-485, 2003. (Pubitemid 38040374)
12. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X, and Hoebe K. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 24: 353-389, 2006.
13. Binck BW, Tsen MF, Islas M, White DJ, Schultz RA, Willis MS, Garcia JV, Horton JW, and Thomas JA. Bone marrowderived cells contribute to contractile dysfunction in endotoxic shock. Am J Physiol Heart Circ Physiol 288: H577-H583, 2005. (Pubitemid 40139640)
14. Bolli R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol 292: H19-H27, 2007. (Pubitemid 46105161)
15. Bottcher T, von Mering M, Ebert S, Meyding-Lamade U, Kuhnt U, Gerber J, and Nau R. Differential regulation of Toll-like receptor mRNAs in experimental murine central nervous system infections. Neurosci Lett 344: 17-20, 2003. (Pubitemid 36627823)
16. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, and O'Neill LA. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci USA 97: 10162-10167, 2000.
17. Boyd JH, Mathur S, Wang Y, Bateman RM, and Walley KR. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 72: 384-393, 2006. (Pubitemid 44665856)
18. Brown MA and Jones WK. NF-kappaB action in sepsis: the innate immune system and the heart. Front Biosci 9: 1201-1217, 2004. (Pubitemid 39060836)
19. Bulut Y, Faure E, Thomas L, Equils O, and Arditi M. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol 167: 987-994, 2001. (Pubitemid 32660856)
20. Cha J, Wang Z, Ao L, Zou N, Dinarello CA, Banerjee A, Fullerton DA, and Meng X. Cytokines link Toll-like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia. Ann Thorac Surg 85: 1678-1685, 2008. (Pubitemid 351608179)
21. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol 296: H1-H12, 2009.
22. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, and Verrier ED. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 128: 170-179, 2004. (Pubitemid 38969797)
23. Chuang T and Ulevitch RJ. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 1518: 157-161, 2001. (Pubitemid 32232289)
24. Chuang TH and Ulevitch RJ. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw 11: 372-378, 2000. (Pubitemid 32268894)
25. Cohen-Sfady M, Nussbaum G, Pevsner-Fischer M, Mor F, Carmi P, Zanin-Zhorov A, Lider O, and Cohen IR. Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. J Immunol 175: 3594-3602, 2005. (Pubitemid 41292018)
26. Cole JE, Georgiou E, and Monaco C. The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm 2010: 393946, 2010.
27. Davani EY, Dorscheid DR, Lee CH, van Breemen C, and Walley KR. Novel regulatory mechanism of cardiomyocyte contractility involving ICAM-1 and the cytoskeleton. Am J Physiol Heart Circ Physiol 287: H1013-H1022, 2004. (Pubitemid 39096645)
28. Diebold SS, Kaisho T, Hemmi H, Akira S, and Reise Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531, 2004. (Pubitemid 38314425)
29. Doyle SE, O'Connell R, Vaidya SA, Chow EK, Yee K, and Cheng G. Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4. J Immunol 170: 3565-3571, 2003. (Pubitemid 36359223)
30. Edfeldt K, Swedenborg J, Hansson GK, and Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105: 1158-1161, 2002. (Pubitemid 34225814)
31. Erickson B, Sperber K, and Frishman WH. Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure. Cardiol Rev 16: 273-279, 2008.
32. Fallach R, Shainberg A, Avlas O, Fainblut M, Chepurko Y, Porat E, and Hochhauser E. Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. J Mol Cell Cardiol 48: 1236-1244, 2010.
33. Faure E, Thomas L, Xu H, Medvedev A, Equils O, and Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 166: 2018-2024, 2001. (Pubitemid 32114690)
34. Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC, Thibault H, Scherrer-Crosbie M, Schmidt U, and Chao W. Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol 295: H1311-H1318, 2008.
35. Ferrandon D, Imler JL, and Hoffmann JA. Sensing infection in Drosophila: Toll and beyond. Semin Immunol 16: 43-53, 2004. (Pubitemid 38147433)
36. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM, and Golenbock DT. LPSTLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 198: 1043-1055, 2003. (Pubitemid 37248620)
37. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal 8: 1907-1939, 2006. (Pubitemid 46504897)
38. Frangogiannis NG, Smith CW, and Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31-47, 2002. (Pubitemid 34020764)
39. Frantz S, Ertl G, and Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 4: 444-454, 2007. (Pubitemid 47180328)
40. Frantz S, Ertl G, and Bauersachs J. Toll-like receptor signaling in the ischemic heart. Front Biosci 13: 5772-5779, 2008.
41. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, and Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104: 271-280, 1999.
42. Gangloff M, Weber AN, Gibbard RJ, and Gay NJ. Evolutionary relationships, but functional differences, between the Drosophila and human Toll-like receptor families. Biochem Soc Trans 31: 659-663, 2003. (Pubitemid 36750751)
43. Geng HL, Lu HQ, Zhang LZ, Zhang H, Zhou L, Wang H, and Zhong RQ. Increased expression of Toll like receptor 4 on peripheral-blood mononuclear cells in patients with coronary arteriosclerosis disease. Clin Exp Immunol 143: 269-273, 2006.
44. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, and Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94: 1621-1628, 1994. (Pubitemid 24309885)
45. Granton JT, Goddard CM, Allard MF, van Eeden S, and Walley KR. Leukocytes and decreased left-ventricular contractility during endotoxemia in rabbits. Am J Respir Crit Care Med 155: 1977-1983, 1997. (Pubitemid 27256128)
46. Ha T, Hua F, Liu X, Ma J, McMullen JR, Shioi T, Izumo S, Kelley J, Gao X, Browder W, Williams DL, Kao RL, and Li C. Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovasc Res 78: 546-553, 2008. (Pubitemid 351769766)
47. Hallman M, Ramet M, and Ezekowitz RA. Toll-like receptors as sensors of pathogens. Pediatr Res 50: 315-321, 2001. (Pubitemid 32801954)
48. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, Guiet C, Briere F, Vlach J, Lebecque S, Trinchieri G, and Bates EE. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 174: 2942-2950, 2005. (Pubitemid 40279713)
49. Hattori Y and Kasai K. Induction of mRNAs for ICAM-1, VCAM-1, and ELAM-1 in cultured rat cardiac myocytes and myocardium in vivo. Biochem Mol Biol Int 41: 979-986, 1997. (Pubitemid 27207627)
50. Hausenloy DJ and Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35: 339-341, 2003. (Pubitemid 36411694)
51. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, and Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410: 1099-1103, 2001. (Pubitemid 32391041)
52. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, and Bauer S. Speciesspecific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529, 2004. (Pubitemid 38314424)
53. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, and Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745, 2000. (Pubitemid 32015992)
54. Hochhauser E, Cheporko Y, Yasovich N, Pinchas L, Offen D, Barhum Y, Pannet H, Tobar A, Vidne BA, and Birk E. Bax deficiency reduces infarct size and improves long-term function after myocardial infarction. Cell Biochem Biophys 47: 11-20, 2007.
55. Hochhauser E, Kaminski O, Shalom H, Leshem D, Shneyvays V, Shainberg A, and Vidne BA. Role of adenosine receptor activation in antioxidant enzyme regulation during ischemia-reperfusion in the isolated rat heart. Antioxid Redox Signal 6: 335-344, 2004. (Pubitemid 38332591)
56. Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, Barhum Y, Pannet H, Shneyvays V, Shainberg A, Goldshtaub V, Tobar A, and Vidne BA. Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. Am J Physiol Heart Circ Physiol 284: H2351-H2359, 2003. (Pubitemid 36622451)
57. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, Goode J, Lin P, Mann N, Mudd S, Crozat K, Sovath S, Han J, and Beutler B. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424: 743-748, 2003. (Pubitemid 37021696)
58. Hoebe K, Janssen E, and Beutler B. The interface between innate and adaptive immunity. Nat Immunol 5: 971-974, 2004. (Pubitemid 41057712)
59. Holvoet P, Davey PC, De Keyzer D, Doukoure M, Deridder E, Bochaton-Piallat ML, Gabbiani G, Beaufort E, Bishay K, Andrieux N, Benhabiles N, and Marguerie G. Oxidized low-density lipoprotein correlates positively with toll-like receptor 2 and interferon regulatory factor-1 and inversely with superoxide dismutase-1 expression: studies in hypercholesterolemic swine and THP-1 cells. Arterioscler Thromb Vasc Biol 26: 1558-1565, 2006. (Pubitemid 44288983)
60. Honda K, Sakaguchi S, Nakajima C, Watanabe A, Yanai H, Matsumoto M, Ohteki T, Kaisho T, Takaoka A, Akira S, Seya T, and Taniguchi T. Selective contribution of IFNalpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci USA 100: 10872-10877, 2003. (Pubitemid 37140120)
61. Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, Hara M, Miyamoto T, Touma M, and Sasayama S. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 38: 1546-1553, 2001. (Pubitemid 33034617)
62. Imler JL and Hoffmann JA. Toll receptors in innate immunity. Trends Cell Biol 11: 304-311, 2001. (Pubitemid 32537777)
63. Janeway CA, Jr. and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20: 197-216, 2002. (Pubitemid 34293424)
64. Janeway CA, Jr. and Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 10: 349-350, 1998. (Pubitemid 28499547)
65. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA, Homer RJ, Goldstein DR, Bucala R, Lee PJ, Medzhitov R, and Noble PW. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11: 1173-1179, 2005. (Pubitemid 43093664)
66. Jones BW, Means TK, Heldwein KA, Keen MA, Hill PJ, Belisle JT, and Fenton MJ. Different Toll-like receptor agonists induce distinct macrophage responses. J Leukoc Biol 69: 1036-1044, 2001. (Pubitemid 32577908)
67. Kaczorowski DJ, Nakao A, Mollen KP, Vallabhaneni R, Sugimoto R, Kohmoto J, Tobita K, Zuckerbraun BS, McCurry KR, Murase N, and Billiar TR. Toll-like receptor 4 mediates the early inflammatory response after cold ischemia/reperfusion. Transplantation 84: 1279-1287, 2007. (Pubitemid 351339316)
68. Kaczorowski DJ, Nakao A, Vallabhaneni R, Mollen KP, Sugimoto R, Kohmoto J, Zuckerbraun BS, McCurry KR, and Billiar TR. Mechanisms of Toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart. Transplantation 87: 1455-1463, 2009.
69. Kaisho T and Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 117: 979-987, 2006; quiz 988.
70. Kambris Z, Hoffmann JA, Imler JL, and Capovilla M. Tissue and stage-specific expression of the Tolls in Drosophila embryos. Gene Expr Patterns 2: 311-317, 2002. (Pubitemid 36356068)
71. Kawai T and Akira S. Innate immune recognition of viral infection. Nat Immunol 7: 131-137, 2006. (Pubitemid 43135878)
72. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, and Lee JO. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906-917, 2007. (Pubitemid 47332573)
73. Kim SC, Ghanem A, Stapel H, Tiemann K, Knuefermann P, Hoeft A, Meyer R, Grohe C, Knowlton AA, and Baumgarten G. Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function. BMC Physiol 7: 5, 2007.
74. Kim SC, Stice JP, Chen L, Jung JS, Gupta S, Wang Y, Baumgarten G, Trial J, and Knowlton AA. Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ Res 105: 1186-1195, 2009.
75. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 6: 88-95, 2004. (Pubitemid 38898835)
76. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N, Entman ML, and Mann DL. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 97: 5456-5461, 2000. (Pubitemid 30313740)
77. Kuwahata S, Fujita S, Orihara K, Hamasaki S, Oba R, Hirai H, Nagata K, Ishida S, Kataoka T, Oketani N, Ichiki H, Iriki Y, Saihara K, Okui H, Ninomiya Y, and Tei C. High expression level of Toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis 209: 248-254, 2010.
78. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, and Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470, 2001. (Pubitemid 32441598)
79. Le Bon A and Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14: 432-436, 2002. (Pubitemid 34671244)
80. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, Sizemore N, and Hwang DH. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 278: 37041-37051, 2003. (Pubitemid 37175218)
81. Li C, Browder W, and Kao RL. Early activation of transcription factor NF-kappaB during ischemia in perfused rat heart. Am J Physiol 276: H543-H552, 1999. (Pubitemid 29100623)
82. Li H and Sun B. Toll-like receptor 4 in atherosclerosis. J Cell Mol Med 11: 88-95, 2007. (Pubitemid 46439627)
83. Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, Carroll JD, Espevik T, Ingalls RR, Radolf JD, and Golenbock DT. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 274: 33419-33425, 1999. (Pubitemid 129511647)
84. Liuzzo G, Angiolillo DJ, Buffon A, Rizzello V, Colizzi C, Ginnetti F, Biasucci LM, and Maseri A. Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. Circulation 103: 2236-2241, 2001. (Pubitemid 32433711)
85. Lund J, Sato A, Akira S, Medzhitov R, and Iwasaki A. Tolllike receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 198: 513-520, 2003. (Pubitemid 36976063)
86. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, and Flavell RA. Recognition of singlestranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 101: 5598-5603, 2004. (Pubitemid 38481202)
87. Lynn M, Rossignol DP, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, Vargas R, D'Angelo T, Gotzkowsky S, and McMahon FG. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 187: 631-639, 2003. (Pubitemid 36250027)
88. Madorin WS, Rui T, Sugimoto N, Handa O, Cepinskas G, and Kvietys PR. Cardiac myocytes activated by septic plasma promote neutrophil transendothelial migration: role of platelet-activating factor and the chemokines LIX and KC. Circ Res 94: 944-951, 2004. (Pubitemid 38490072)
89. Massey KD, Strieter RM, Kunkel SL, Danforth JM, and Standiford TJ. Cardiac myocytes release leukocytestimulating factors. Am J Physiol 269: H980-H987, 1995.
90. McDonald TE, Grinman MN, Carthy CM, and Walley KR. Endotoxin infusion in rats induces apoptotic and survival pathways in hearts. Am J Physiol Heart Circ Physiol 279: H2053-H2061, 2000.
91. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-145, 2001. (Pubitemid 33741967)
92. Medzhitov R and Janeway CA, Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91: 295-298, 1997. (Pubitemid 27467959)
93. Medzhitov R, Preston-Hurlburt P, and Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397, 1997. (Pubitemid 27334820)
94. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, and Janeway CA, Jr. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 2: 253-258, 1998. (Pubitemid 128373651)
95. Meier A, Kirschning CJ, Nikolaus T, Wagner H, Heesemann J, and Ebel F. Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol 5: 561-570, 2003. (Pubitemid 36939595)
96. Meng X, Ao L, Brown JM, Fullerton DA, Banerjee A, and Harken AH. Nitric oxide synthase is not involved in cardiac contractile dysfunction in a rat model of endotoxemia without shock. Shock 7: 111-118, 1997. (Pubitemid 127654257)
97. Meng X, Ao L, Brown JM, Meldrum DR, Sheridan BC, Cain BS, Banerjee A, and Harken AH. LPS induces late cardiac functional protection against ischemia independent of cardiac and circulating TNF-alpha. Am J Physiol 273: H1894-H1902, 1997.
98. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, and Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 111: 2654-2661, 2005. (Pubitemid 40740866)
99. Mizel SB, Honko AN, Moors MA, Smith PS, and West AP. Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes. J Immunol 170: 6217-6223, 2003. (Pubitemid 36682606)
100. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, and Rossignol DP. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 304: 1093-1102, 2003. (Pubitemid 36254422)
101. Muzio M, Polentarutti N, Bosisio D, Prahladan MK, and Mantovani A. Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol 67: 450-456, 2000.
102. Nemoto S, DeFreitas G, Mann DL, and Carabello BA. Effects of changes in left ventricular contractility on indexes of contractility in mice. Am J Physiol Heart Circ Physiol 283: H2504-H2510, 2002. (Pubitemid 35345956)
103. Nian M, Lee P, Khaper N, and Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94: 1543-1553, 2004. (Pubitemid 38856961)
104. Niessen HW, Lagrand WK, Visser CA, Meijer CJ, and Hack CE. Upregulation of ICAM-1 on cardiomyocytes in jeopardized human myocardium during infarction. Cardiovasc Res 41: 603-610, 1999. (Pubitemid 29130624)
105. Ohashi K, Burkart V, Flohe S, and Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164: 558-561, 2000. (Pubitemid 30043672)
106. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, and Strauss JF, 3rd. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276: 10229-10233, 2001.
107. O'Neill LA. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 3: 396-403, 2003. (Pubitemid 36913535)
108. O'Neill LA, Fitzgerald KA, and Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 24: 286-290, 2003.
109. Oyama J, Blais C, Jr., Liu X, Pu M, Kobzik L, Kelly RA, and Bourcier T. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109: 784-789, 2004. (Pubitemid 38222900)
110. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, and Aderem A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 97: 13766-13771, 2000.
111. Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, McCabe C, Welch SB, Whitney A, O'Gara P, Nadel S, Relman DA, Harding SE, and Levin M. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 363: 203-209, 2004. (Pubitemid 38114718)
112. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, Cohen S, Cohen IR, and Zipori D. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109: 1422-1432, 2007. (Pubitemid 46239573)
113. Pinsky MR. Dysregulation of the immune response in severe sepsis. Am J Med Sci 328: 220-229, 2004. (Pubitemid 39372464)
114. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, and Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088, 1998. (Pubitemid 29001265)
115. Poon BY, Raharjo E, Patel KD, Tavener S, and Kubes P. Complexity of inducible nitric oxide synthase: cellular source determines benefit versus toxicity. Circulation 108: 1107-1112, 2003. (Pubitemid 37071522)
116. Prince JM, Levy RM, Yang R, Mollen KP, Fink MP, Vodovotz Y, and Billiar TR. Toll-like receptor-4 signaling mediates hepatic injury and systemic inflammation in hemorrhagic shock. J Am Coll Surg 202: 407-417, 2006. (Pubitemid 43356214)
117. Qureshi ST, Zhang X, Aberg E, Bousette N, Giaid A, Shan P, Medzhitov RM, and Lee PJ. Inducible activation of TLR4 confers resistance to hyperoxia-induced pulmonary apoptosis. J Immunol 176: 4950-4958, 2006.
118. Raeburn CD, Calkins CM, Zimmerman MA, Song Y, Ao L, Banerjee A, Harken AH, and Meng X. ICAM-1 and VCAM-1 mediate endotoxemic myocardial dysfunction independent of neutrophil accumulation. Am J Physiol Regul Integr Comp Physiol 283: R477-R486, 2002. (Pubitemid 34863896)
119. Raeburn CD, Dinarello CA, Zimmerman MA, Calkins CM, Pomerantz BJ, McIntyre RC, Jr., Harken AH, and Meng X. Neutralization of IL-18 attenuates lipopolysaccharideinduced myocardial dysfunction. Am J Physiol Heart Circ Physiol 283: H650-H657, 2002. (Pubitemid 34790859)
120. Re F and Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 276: 37692-37699, 2001.
121. Riad A, Jager S, Sobirey M, Escher F, Yaulema-Riss A, Westermann D, Karatas A, Heimesaat MM, Bereswill S, Dragun D, Pauschinger M, Schultheiss HP, and Tschope C. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol 180: 6954-6961, 2008.
122. Roger T, Froidevaux C, Le Roy D, Reymond MK, Chanson AL, Mauri D, Burns K, Riederer BM, Akira S, and Calandra T. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci USA 106: 2348-2352, 2009.
123. Ryter SW, Kim HP, Hoetzel A, Park JW, Nakahira K, Wang X, and Choi AM. Mechanisms of cell death in oxidative stress. Antioxid Redox Signal 9: 49-89, 2007. (Pubitemid 44901874)
124. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, and Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation 95: 320-323, 1997. (Pubitemid 27056193)
125. Satoh M, Nakamura M, Akatsu T, Iwasaka J, Shimoda Y, Segawa I, and Hiramori K. Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis. Clin Sci (Lond) 104: 577-584, 2003. (Pubitemid 36713847)
126. Schletter J, Brade H, Brade L, Kruger C, Loppnow H, Kusumoto S, Rietschel ET, Flad HD, and Ulmer AJ. Binding of lipopolysaccharide (LPS) to an 80-kilodalton membrane protein of human cells is mediated by soluble CD14 and LPS-binding protein. Infect Immun 63: 2576-2580, 1995.
127. Schoneveld AH, Hoefer I, Sluijter JP, Laman JD, de Kleijn DP, and Pasterkamp G. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis 197: 95-104, 2008. (Pubitemid 351273277)
128. Shen XD, Ke B, Zhai Y, Gao F, Tsuchihashi S, Lassman CR, Busuttil RW, and Kupiec-Weglinski JW. Absence of toll-like receptor 4 (TLR4) signaling in the donor organ reduces ischemia and reperfusion injury in a murine liver transplantation model. Liver Transpl 13: 1435-1443, 2007. (Pubitemid 47629578)
129. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring DJ, Pohlman TH, Shimpo H, and Verrier ED. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 114: I270-I274, 2006. (Pubitemid 44297162)
130. Shiraki R, Inoue N, Kobayashi S, Ejiri J, Otsui K, Honjo T, Takahashi M, Hirata K, Yokoyama M, and Kawashima S. Toll-like receptor 4 expressions on peripheral blood monocytes were enhanced in coronary artery disease even in patients with low C-reactive protein. Life Sci 80: 59-66, 2006. (Pubitemid 44809296)
131. Simms MG and Walley KR. Activated macrophages decrease rat cardiac myocyte contractility: importance of ICAM-1-dependent adhesion. Am J Physiol 277: H253-H260, 1999. (Pubitemid 29354700)
132. Solomon SB, Cui X, Gerstenberger E, Danner RL, Fitz Y, Banks SM, Natanson C, and Eichacker PQ. Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J Infect Dis 193: 634-644, 2006. (Pubitemid 43271497)
133. Szabo C. Role of flagellin in the pathogenesis of shock and acute respiratory distress syndrome: therapeutic opportunities. Crit Care Med 31: S39-S45, 2003. (Pubitemid 36143476)
134. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, and Akira S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and grampositive bacterial cell wall components. Immunity 11: 443-451, 1999. (Pubitemid 29504199)
135. Takeuchi O, Kawai T, Sanjo H, Copeland NG, Gilbert DJ, Jenkins NA, Takeda K, and Akira S. TLR6: A novel member of an expanding toll-like receptor family. Gene 231: 59-65, 1999. (Pubitemid 29307773)
136. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, Lathia JD, Siler DA, Chigurupati S, Ouyang X, Magnus T, Camandola S, and Mattson MP. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 104: 13798-13803, 2007. (Pubitemid 350003400)
137. Tavener SA and Kubes P. Is there a role for cardiomyocyte toll-like receptor 4 in endotoxemia? Trends Cardiovasc Med 15: 153-157, 2005. (Pubitemid 41297624)
138. Tavener SA, Long EM, Robbins SM, McRae KM, Van Remmen H, and Kubes P. Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circ Res 95: 700-707, 2004. (Pubitemid 39331930)
139. Thomas JA, Haudek SB, Koroglu T, Tsen MF, Bryant DD, White DJ, Kusewitt DF, Horton JW, and Giroir BP. IRAK1 deletion disrupts cardiac Toll/IL-1 signaling and protects against contractile dysfunction. Am J Physiol Heart Circ Physiol 285: H597-H606, 2003. (Pubitemid 36885890)
140. Thompson M, Kliewer A, Maass D, Becker L, White DJ, Bryant D, Arteaga G, Horton J, and Giroir BP. Increased cardiomyocyte intracellular calcium during endotoxininduced cardiac dysfunction in guinea pigs. Pediatr Res 47: 669-676, 2000. (Pubitemid 30249858)
141. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, Piek JJ, Pasterkamp G, and de Kleijn DP. Tolllike receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 102: 257-264, 2008. (Pubitemid 351674064)
142. Triantafilou M and Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 23: 301-304, 2002. (Pubitemid 34628773)
143. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, and Aderem A. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401: 811-815, 1999.
144. Versteeg D, Hoefer IE, Schoneveld AH, de Kleijn DP, Busser E, Strijder C, Emons M, Stella PR, Doevendans PA, and Pasterkamp G. Monocyte toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve. Heart 94: 770-776, 2008. (Pubitemid 351744698)
145. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 61: 481-497, 2004. (Pubitemid 38210154)
146. Wang YP, Sato C, Mizoguchi K, Yamashita Y, Oe M, and Maeta H. Lipopolysaccharide triggers late preconditioning against myocardial infarction via inducible nitric oxide synthase. Cardiovasc Res 56: 33-42, 2002. (Pubitemid 35247800)
147. Wright G, Singh IS, Hasday JD, Farrance IK, Hall G, Cross AS, and Rogers TB. Endotoxin stress-response in cardiomyocytes: NF-kappaB activation and tumor necrosis factoralpha expression. Am J Physiol Heart Circ Physiol 282: H872-H879, 2002. (Pubitemid 34654922)
148. Wyllie DH, Kiss-Toth E, Visintin A, Smith SC, Boussouf S, Segal DM, Duff GW, and Dower SK. Evidence for an accessory protein function for Toll-like receptor 1 in antibacterial responses. J Immunol 165: 7125-7132, 2000. (Pubitemid 32001188)
149. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, and Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104: 3103-3108, 2001. (Pubitemid 34014065)
150. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, and Akira S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301: 640-643, 2003. (Pubitemid 36927946)
151. Yellon DM and Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 357: 1121-1135, 2007.
152. Zarember KA and Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 168: 554-561, 2002. (Pubitemid 34049553)
153. Zeuke S, Ulmer AJ, Kusumoto S, Katus HA, and Heine H. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res 56: 126-134, 2002. (Pubitemid 35247809)
154. Zhang G and Ghosh S. Toll-like receptor-mediated NFkappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 107: 13-19, 2001. (Pubitemid 32047406)
155. Zhang X, Shan P, Qureshi S, Homer R, Medzhitov R, Noble PW, and Lee PJ. Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury. J Immunol 175: 4834-4838, 2005. (Pubitemid 41456364)
156. Zhao P, Wang J, He L, Ma H, Zhang X, Zhu X, Dolence EK, Ren J, and Li J. Deficiency in TLR4 signal transduction ameliorates cardiac injury and cardiomyocyte contractile dysfunction during ischemia. J Cell Mol Med 13: 1513-1525, 2009.
157. Zhu X, Zhao H, Graveline AR, Buys ES, Schmidt U, Bloch KD, Rosenzweig A, and Chao W. MyD88 and NOS2 are essential for toll-like receptor 4-mediated survival effect in cardiomyocytes. Am J Physiol Heart Circ Physiol 291: H1900-H1909, 2006. (Pubitemid 44497698)